Biotechnology 2009 India

India
Biotechnology Industry
Compiled by
Swiss Business Hub India
October 2009
Download from: www.osec.ch

1. Overview and Trends
The Indian biotechnology sector is one of the fast growing knowledge-based industries in India and is expected
to play a key role in shaping India's rapidly developing economy. Presently, India is ranked among the top 12
biotech players in the world, and is the third biggest in Asia-Pacific in terms of the number of biotech
companies. The investments in this industry have been growing robustly over the past few years and have
reached at US$ 637 million. The industry had achieved annual turnover worth US$ 2.5 billion in fiscal year
1
2007–08 , after having registered a compound annual growth rate (CAGR) of more than 25 per cent over the
previous few years. Around 50 per cent of the total biotech market is shared among the 20 leading companies
in the country. The export accounts for nearly 55 percent while the domestic consumption accounts for nearly
45 percent of this industry. The current global financial and economic slowdown has certainly made an impact
on this industry.
India contributes around 2 percent of the global biotech industry. There are some 325 biotechnology
companies operating in the country, employing around 20,000 scientists. The industry can be divided into five
distinct segments – biopharmaceuticals, bio-services, bio-agriculture, bio-industrial, and bioinformatics.
According to the fifth survey on the industry conducted by Biospectrum and Association of Biotechnology Led
Enterprises (ABLE) jointly, nearly 40 percent of the companies operate in the bio-pharma sector, followed by
the bio-services (21 percent), bio-agri (19 percent), bioinformatics (14 percent) and lastly the bio-industrial
segment (5 percent).
India has over 100 research organizations in the country focused on different areas of research in the
biotechnology area. The government has been playing a proactive role to promote this industry. It has recently
launched a Biotechnology Industry Partnership Programme to provide industry the support by cost sharing on
high risk discovery and innovation projects. The programme is being funded by a budget outlay of US dollars
74 million during the current 5-year Plan. The major objective of this programme is to increase the global
competitiveness of Indian industry in new and promising technologies. The said package will underwrite the
risk of research and development of innovative molecules and processes. It will be open to all innovative
biotechnology companies, which are looking to do research in agriculture, health, bio-energy and green
manufacturing. This helps to also fulfil the Department of Biotechnology’s strategy to spend 30% of its R&D
investment in partnership with industry. The country is already laying down some strong foundations, which will
eventually help the industry to increase its share in the global market. The examples include setting up of
Centres of Excellence and expanding the educational and research facilities.
2. Indian Biotechnology Industry
The Indian Biotechnology industry was slow to start, but has been gaining momentum for the past couple of
years. Although, the current share in the global biotech market is relatively low, but it has necessary potential to
become a prominent player in this market. According to the latest survey carried out by Association of Biotech
Led Enterprises (ABLE), the biotechnology industry in India has notched up a growth of 20 per cent during
2007–08 and the revenues earned were worth US$ 2.56 billion as against US$ 2.1 billion during the previous
fiscal. The biotech industry had recorded average growth of more than 30 percent in some of the previous
years. The following chart shows the growth pattern of the industry between fiscal years 2003-04 and 2007-08.
1
The Indian fiscal year runs from 1st April to 31st March
Download: www.osec.ch 2 / 31
Biotech Industry 2003-2007
1800
1600
Revenue (US$ million)
1400
1200
1000
800
600
400
200
0
2003-04 2004-05 2005-06 2006-07 2007-08
Bio-pharma 671 871 1148 1457 1683

Bio-services 67 104 176 269 383
Bio-agri 32 80 146 226 293
Bio-industry 58 78 91 96 100
Bio-informatics 20 24 29 35 46
The bio-pharma is the industry's largest segment accounting for 67 per cent of the overall revenues, as per
2007-08 data. The shares of other segments are: bio-services (15 percent), bio-agri (12 percent), bio-industrial
(4 percent) and bio-informatics (2 percent). As mentioned above, this industry has a strong export linkage.
Biotech Industry- Exports Vs Domestic Sales 2007-08
Bio-pharma 976 707
Bio-services 366 17
Bio-agri 12 281
Bio-industrial 7 93
Bio-informatics 37 9
0 200 400 600 800 1000 1200 1400 1600 1800

US$ million
Exports Domestic
Source: India Brand Equity Foundation – IBEF / ABLE-Biospectrum Survey
The bio-pharma industry is accounted for largely by research, development and production of bio-similars or
follow-on biologics – copies of established biologic drugs. Gaining strength from the ongoing R&D, the bio-
pharma segment is expected to reach US$ 5.5 billion by fiscal 2013. The total bio-pharma industry, consisting
of therapeutics, vaccines, diagnostics, and other products such as statins, recorded a massive 26.9% growth in
fiscal year 2007 and continues to be largest contributor to the overall biotech market in the country. The good
performance of the bio-pharma sector is attributed to the strongly growing vaccine business which accounted
for about 50% of the total bio-pharma business in fiscal year 2007. Interestingly, India is one of the largest
producers of traditional vaccines in the world. The producers of Hepatitis B vaccine continue to register robust
growth, and more and more companies are focusing on under-served markets such as HIV, Japanese
Encephalitis and high-value combination vaccines. The vaccine business will remain dynamic in future, taking
the overall bio-pharma market up. Diagnostics and therapeutics businesses, which account for about 16
percent and 12 percent respectively of the bio-pharma market, are driven by a rise in chronic diseases and
huge investments being poured into the healthcare infrastructure with several path labs and hospitals opening
up in India. The bio-pharma sector will further get a drive from the fact the India is forecasted to become a key
bio-generics supplier to the developed world in near future. Notably, the top five players in bio-pharma segment
have a 45 percent share of the market, and out of the top ten companies, seven are vaccine manufactures.
The following chart shows the prominence of bio-pharma segment in the total export of biotech
products/services from India:
Share of different segments in biotech exports during 2007-08
1% 2%
1%
26%
70%
Bio-pharma Bio-services Bio-agri Bio-industrial Bio-informatics
Source: Indian Brand Equity Foundation – IBEF / Biospectrum
As per a KPMG report, the Indian firms have a huge advantage over their counterparts in western markets
because of relatively lower R&D costs, so the industry can afford to be somewhat less risk-averse. The
country’s drug industry is building product capabilities in bio-similars, particularly in products such as
recombinant insulin, GCSF, interferon alpha, erythropoietin, and has started to move into monoclonal antibody
(MAb) products and recombinant vaccines. Other fast growing areas include bio-engineering, which develops
new tissue engineering processes and biomaterials for therapeutics. India is also trying to play a prominent role
in the genomics space. The Indian genes have been mapped and now the country is moving towards open
source drug discovery. About INR 5 billion will be allocated for this, which is good for the industry and the
society.
The Indian law allows stem cell research for therapeutic cloning, but prohibits reproductive cloning. The Indian
Council of Medical Research and the Department of Biotechnology have laid down the Guidelines for Stem Cell
Research and Therapy for adult, cord blood and embryonic stem cells in response to the support provided by
the Government to facilitate stem cell research in India so as to improve understanding of human health and
disease, and evolve strategies to treat serious diseases. The government plans include setting up an exclusive
fund to support stem cell research in the country. There are also initiatives taken by the private sector to foster
research in this field. For example, the Reliance Life Sciences Institute has a good ranking amongst the top
institutes worldwide working on stem cell research.
India shows promising potential and is fast becoming an important hub for outsourcing of clinical trials and
contract research. The key success factors for India are - a large pool of qualified scientists and engineers,
institutional infrastructure, existing and upcoming cost-competitive research facilities, and a diversified patient
pool. Besides this, the country also has diverse species of flora and fauna that give the added advantage for
biotech companies to carry on their research and drug discovery effectively. With the new legislation putting in
place a product patent regime post 2005, the business conditions for bio-services have been further improved.
According to a report by RNCOS, the aforesaid factors would help India to increase its share in the global
clinical trials from less than 2 percent (2007) to 5 percent by 2012. The burgeoning clinical trials market in India
is likely to create more business opportunities for a number of associated industries, including in vitro
diagnostics market, data management, as well.
India is ranked fourth in the world among Bt crops growing countries, in terms of cultivated hectares. The bio-
agri is driven primarily by Bt cotton seeds, as these seeds market alone was estimated to be worth US$ 203
million last year. The bio-pesticides and bio-fertilizers estimated to have a combined market value of US$ 19.5
million in the country, and among bio-fertilizers, phosphate-solubilising micro-organisms market witnessed the
highest growth. The country gave its nod for commercial cultivation of Bt cotton in early 2002. After six years, in
2008, 30 seed companies were engaged in production of 274 Bt cotton hybrids. Growing manifold, the Bt
cotton acreage today accounts for about 80 per cent of the total area under cotton cultivation. Parallel with the
introduction of Bt cotton, the yield of cotton increased from 308 kg/ha in 2002 to 560 kg/ha in 2008 and is
projected to increase to 591 kg/ha in 2009. This has generated impressive economic gains for Indian farmers
and enabled India to emerge as a net exporter of cotton from being a net importer. Remarkably, India emerged
as the world’s second largest cotton producer in fiscal year 2007. According to a study report by Rabo India
Finance Limited Indeed, the country has the potential to also become a major producer of transgenic rice and
several genetically modified (GM) or engineered vegetables. The research work is being carried in many crops.
These include rice, cotton, eggplant, potato, tomato, corn, cabbage, castor, citrus fruit, black gram, and
groundnut. Bt. Brinjal (eggplant) is the first biotech vegetable food crop, which is under consideration of the
regulatory body for commercial approval in 2009. No doubt, the bio-agri continues to be one of the fastest
growing segments in the overall biotech industry.
A diverse set of Indian companies is involved in the development of innovative technology in the bio-diesel
area, which is well supported by the government in order to decrease the reliance on imported fuel. India has
recently initiated a Bio-fuel Policy which seeks to convert at least a major part of the 60 million hectares of
wastelands into farmlands for oil-bearing crops which can produce bio-diesel in plenty. There is no doubt that
this policy will give further boost to the existing efforts by the private and public sector institutions to ensure the
nation's energy security. The policy has set an ambitious target of 20 percent blended bio-diesel by 2017. This
means a production of 15-16 million tons of bio-diesel and a coverage area of over 30 million acres of bio-fuel
plantation. Though the policy has been announced only less than a year ago, some companies, e.g. Reliance,
have made significant investment in the bio-fuels arena by now.
The bioinformatics sector is successfully creating synergies between the IT and biotechnology industry.
Certainly, the bioinformatics industry benefits from the strength of the IT industry in India. There are three
distinct kinds of bioinformatics companies in India now. Almost all the large IT services companies in India
have been looking at bioinformatics with interest from as early as the year 2001. The major Indian IT
companies have large life sciences divisions. In terms of overall size, some estimates run close to $1 billion in
business that this segment generates for the IT services companies, although the actual bioinformatics content
of what many of these companies do is difficult to measure. A second group consists of companies that began
as start-ups a few years ago. Notably, some early bioinformatics companies have turned into broader contract
research organizations and their bioinformatics business has become a minor part of their strategy. The third is
captive bioinformatics groups within large pharmaceutical and biotechnology companies that use some
bioinformatics for their research. Some of the big IT companies offer services relating to data mining, scientific
visualization, information storage or simulation of DNA sequences. The global bioinformatics market is
expected to grow at a CAGR of 16 per cent over 2007–10, whereas in India the growth is expected to be at a
higher rate - 25 percent. Though the Indian bioinformatics sector is growing rapidly, its share in the global
market is still miniscule. With a general revival of fortunes in the genomics, the business prospects for bio-
informatics companies look good.
The bio-industry segment is concentrated with 70 percent of India’s enzyme market. There are some 15
companies in India that are involved in the enzymes business. There are also players with focus on new areas
of application, such as food processing, animal nutrition, dairy, aquaculture, marine etc. According to a Frost &
Sullivan study, growing awareness and increased investments have led to the growth of biotechnology
applications in the food and beverage and dietary supplements sector. The Indian food processing industry has
seen some promising product developments such as probiotic fortified yoghurt, buttermilk, omega fortified
health drinks and baby foods. A lot more can be achieved through cutting edge R&D in the meadow of
biotechnology resulting in innovative food and beverage products with improved functional and health benefit.
India’s top biotech companies as per the survey conducted by Biospectrum magazine and ABLE are as
follows:
Top 20 Biotech Companies (Revenue-wise)
Rank Company 2007-08 2006-07 Y-o-Y

2008 Revenue( INR mio). Revenue (INR mio.) Growth
1. Serum Institute of India 9870.00 9509.50 4%
2. Biocon 9120.00 8490.00 7%
3. Panacea Biotec 6779.80 7011.30 -3%
4. Nuziveedu Seeds 3030.00 2264.20 33.8%
5. Rasi Seeds 2932.80 3333.30 -12%
6. Novo Nordisk 2600.00 2220.00 17%
7. Novozymes South Asia 2250.00 1000.00 125%
8. Indian Immunologicals 1960.00 1579.00 24%
9. Mahyco 1700.00 1106.90 54%
10. Syngene International 1600.00 1320.00 21%
11. Jubilant 1590.00 - -
12. Shantha Biotechnics 1500.00 1150.00 30%
13. Bharat Serums 1400.00 1084.90 29%
14. Eli Lilly 1370.00 1140.00 20%
15. Bharat Biotech 1260.00 700.00 80%
16. Themis Medicare 1100.00 680.00 62%
17. Aventis 1050.00 1196.50 -12%
18. Haffkine Biopharma 886.10 656.90 35%
19. Rossari Biotech 820.00 660.00 24%
20. GlaxoSmithKline 804.00 790.00 2%
Industry’s Overall Revenue 102737.00 85410.00 20%
Exchange rate: 1 USD = 41 INR
India has a number of biotech clusters, and these are located mainly in Bangalore (Karnataka), Pune-Mumbai
(Maharashtra), Hyderabad (Andhra Pradesh), NCR Delhi, and Ahmedabad-Vadodara (Gujarat). The other
major locations for biotech industry include Kolkata and Lucknow. Bangalore has the largest number of biotech
companies in the country. Hyderabad has witnessed a lot of infrastructural development in the biotech domain
wherein a Knowledge Park, Biotech Park, Genome Valley and other projects are operational giving this city an
advantage over many others. As the government has adopted a proactive policy on setting up of industry-
specific special economic zones, many public and private enterprises are in the process to set up new biotech
zones/parks in the country.
The industry is now aiming to achieve a revenue of $5 billion by 2010. This optimistic outlook has its roots in
foreign companies increasingly investing in India. According to industry players, escalating research and
development expenses and stringent policies are making manufacturers from the regulated markets look
towards India for cutting costs. A Frost and Sullivan report says that multinational pharmaceutical and
biotechnology companies from western Europe and the US are using India and China for their phased studies
on emerging markets. Besides, cheaper clinical trials and extra benefits, such as availability of good technical
abilities, are boosting foreign investments, says the report. The pharmaceutical manufacturing hubs such as
Delhi, Mumbai, Chennai, Ahmedabad, Hyderabad and Bangalore are fast improving their abilities to provide
enhanced collaborative and outsourced R&D services. Currently, such services include drug discovery and
validation processes, and, in the fields of pathway analysis (study of effect of toxic or radioactive substances on
humans), genomics (study of gene sequences), proteomics (study of proteins) and translational research
(investigation and experiments on patients and volunteers). In this context, Kiran Mazumdar-Shaw,
Chairperson and Managing Director, Biocon group, a leading biotech company, has said, "Co-development
agreements are leading to interesting models." Many leading Indian biotech companies have entered into
collaborative arrangements with overseas companies, such as Merck & Company, GSK, Eli Lilly, Bristol Myers
Squibb, and Ortho-McNeil Janssen.
Over the last few years, Asia, and more so India, has been a high growth market for the global life science
suppliers. Almost all the global majors like Agilent Technologies, Bio-Rad, GE Healthcare, Invitrogen, Millipore,
Pall, Perkin Elmer, Shimadzu, Thermo Electron, and Waters Corporation have strengthened their presence and
market hold in India. These global companies are consolidating their presence in India for two main reasons.
One, growing Indian market has become more important for foreign companies. The other reason is to
leverage the skilled manpower in terms of R&D activities in India. The demand for all the products - separation,
instrumentation, mass spectrometry, surface sciences, lab automation, or general lab equipment - is on the rise
mainly from the generic drug manufacturers and contract research organizations. With strong growth in R&D
and production, the bio-supplier industry is also on a robust growth path, almost 30 percent growth annually.
Some of the developments in recent times bear testimony to the robust growth momentum in Indian biotech
industry:
• According to a report released by Med Ad News last year, Biocon had found a place amongst top 25
biotechnology companies worldwide. Biocon Limited was the only Asian company to feature in this
ranking at number 20. The companies were ranked according to their revenues.
• Serum Institute of India is possibly the world’s largest vaccine manufacturer of measles and DTP
vaccines.
• Biocon is the largest manufacturer of insulin in Asia.
• Asia's first and the world's second human DNA bank has been set up at the Biotech Park in India (Uttar
Pradesh State). The members of the DNA bank will receive a microchip-based DNA card containing
information of their fingerprints, and anthropological details.
• Biovel, an integrated biotechnology firm, launched Asia's first Bio Safety Level-4 (BSL-4)
manufacturing facility, specifically designed to facilitate product development and manufacturing of
vaccines like Foot and Mouth Disease vaccine (FMD).
3. Potential Growth of the Biotechnology Industry
According to a report jointly prepared by the Confederation of Indian Industry (CII) and KPMG some time back,
the Indian biotechnology sector has excellent potential and is expected to touch US $5 billion mark by 2010. No
doubt this sector, like many other sectors, is feeling the impact of the present global economic slowdown.
Therefore, attaining the US$ 5 billion mark may not be so easy now.
Nevertheless, the following factors will be driving the growth:

Growing population and improving incomes
Emerging lifestyle diseases
Increasing investment in infrastructure and R&D, both by public and private sectors
Increasing outsourcing opportunities in the manufacturing
Emerging contract research market
The bio-pharma segment is expected to continue its dominance in the overall Indian market. The vaccine
manufacturers will certainly be the leading force. With respect to diagnostics, many products are being
imported into the country, but at the same time there is a new competitiveness emerging from the local players.
Furthermore, the therapeutics remain the thrust in Indian R&D, with human insulin being the most common
area of research. The reason is that India has over 37.5 million people suffering from diabetes and the number
is rising. India has 25 per cent of the world’s haemophiliac population, therefore plasma proteins is an
emerging market here. The country has been sourcing plasma proteins from MNCs such as Baxter, and no
doubt there is good potential for manufacturing plasma proteins locally and indigenously. Monoclonal
Antibodies (mAbs) are also a fast-growing market especially in oncology and auto-immune diseases.
Furthermore, India has 3 million cancer patients and 700,000 new cases are added every year, that is why
more and more Indian companies are looking for collaborations with foreign companies in this field. Indian bio-
pharma companies are also looking to compete in the space of New Biological Entities and make them a key
source of growth in the long term. They are exploring partnership models such as joint product development
and joint marketing to build a distinguished presence in this segment.
Bio-agri is also developing quite well in India. The country is the second largest food producer after China and
therefore, offers enormous opportunities for transgenic crops. The usage of Bt cotton has made a remarkable
impact on the farming community. The Indian farmer has been quick (than what was perceived earlier) to adopt
new technology as he could see real value in it. The commercial approval of more transgenic plants is likely to
push further growth in this segment. According to an analysis, if bio-fertilizers were used to substitute 25
percent of chemical fertilizers on 50 percent of India’s crop, the market potential would be 235 thousand MT,
compared to only 13 thousand MT now. Also, the bio-pesticides are expected to grow at an annual rate of 10-
15 percent in the short term.
Similarly, the business prospects in bio-services, bio-informatics, and bio-industrial are enormous as India
continues to offer cost-competitive “eco system” for biotech companies. In bio-industrial area, the segments like
industrial enzymes and renewable energy hold good business prospects.
4. Government Initiatives
The Indian government has been consistently endeavouring to provide and foster an environment conducive to
biotech development since 1986. The government approved a national biotechnology development strategy
last year. It was an outcome of a long nationwide consultation process involving multiple stakeholders. A key
element of the strategy is the setting up of a National Biotechnology Regulatory Authority (NBRA). This will
provide a single window biosafety clearance of genetically modified products/processes. This is something that
the industry has been demanding for a long time as, without such an institution, the release of biotech products
into the Indian market gets unduly delayed. Presently, a draft bill for the establishment of NBRA is being
circulated for inter-ministerial consultation.
The Department of Biotechnology is pushing for increasing public-private partnerships in research and
development. DBT has earmarked 30 per cent of its budget for such collaborative research. The government
has also launched a Biotechnology Industry Partnership Programme (BIPP) and a Biotechnology Industry
Research Assistance Programme (BIRAP). These schemes are one of the most enabling mechanisms to
promote biotech industry R&D and public private partnership programmes. The government aims to support
the industry also by expanding the pool of researchers, creating a higher quality technical workforce, and
creating industrial platforms, that can eventually build sustainable growth for the biotech sector. Establishing
partnerships with key foreign countries active in biotech is also a remarkable initiative by the Indian
government. This has been helping the country to adopt the best practices out of the shared experiences,
thereby improving the R&D infrastructure.
The government is trying to boost the sector by facilitating requisite infrastructure in terms of biotech parks
(some examples are TICEL Bio Park in Hyderabad, Tidel Park in Chennai) and Special Economic Zones.
Some new technology clusters are being planned in the various fields of biotechnology. For example,
discussions are being held to set up a biotechnology cluster in the University of Agricultural Sciences,
Bangalore campus close to National Centre for Biological Sciences. The government has also initiated a
project to conduct genome-wide research on a range of agronomically important crops.
In order to facilitate foreign direct investment in the biotechnology sector, all project proposals exceeding FDI of
US $ 22 million, are handled by the Department of Biotechnology (DBT)’s Fast track Committee. The DBT has
also taken initiatives to link 63 bioinformatics centres in India to promote networking of information resources.
The availability of funds for DBT has been drastically increased by the government. During the current 5-year
Plan (2007-2012), the biotechnology sector receives government funding amounting to INR 65 billion as
compared to INR 14.5 billion in the previous 5-year Plan.
The followings are some of the incentives being offered generally by the Indian government to the
biotechnology sector:
Allows Income Tax benefit - weighted deduction of 150% for R&D expenditure as well as on
international patenting costs until 2012.
Offers exemption/concession on import duties on specified items for R&D and clinical trial equipment.
Offers Service tax exemption on clinical trials of new drugs including vaccines and herbal remedies.
Considering biotechnology for priority sector lending, the government encourages banks to lend money
to biotech companies.
Offers Excise duty and Sales tax exemption for bio-diesel.
Offers tax benefits to Venture Capitalists investing in biotech industry.
Offers support for industry research under the “New Millennium India Technology Leadership Initiative
(NMITLI)”. It has been launched to catalyze innovation oriented scientific and technological
developments in selected niche areas by synergizing the best competencies of publicly funded R&D
institutions, academia and private industry. Two broad categories of projects are supported under
NMITLI – nationally evolved projects and industry originated projects. Financial support will be provided
under NMITLI in the form of Grants-in-Aid to institutional partners in public domain and as soft loan.
With its Small Business Innovation Research Initiative (SBIRI) for a small and medium business unit
(the company should have a well established in-house R&D unit with not more than 500 employees
and recognized by Department of Scientific and Industrial Research), the government offers an
alternative financing possibility for biotech start ups. Generally and subject to fulfilment of the terms
and conditions laid down by the Department of Biotechnology, a start-up is provided up to a maximum
of US$ 100,000 as a grant in a first phase to enable the company to undertake innovative pre-proof-of-
concept research and late stage development and commercialization of the innovation research.
Further financial assistance is offered as soft loan carrying interest rates ranging from 1-2 percent.
Furthermore, the advanced companies are offered equity financing through the SME Growth Fund of
Small Industries.
The Ministry of Science and Technology is promoting a number of centres of excellence for
biotechnology. These institutes with state-of the art technology and highly skilled labour collaborate
with the private industry.
5. Conclusions
India is already globally recognised as a manufacturer of economical, high quality bulk drugs and formulations.
The opportunities in the bio-pharma segment are promising. For example, the bio-pharma companies are
already playing an important role in the global vaccines market. With many more innovative indigenous
recombinant therapeutic products in the pipeline, and with USFDA-compliant facilities, the business prospects
look quite bright. With regard to clinical trials, India offers many advantages in this particular space, and that is
why it is able to create a win-win situation for more collaboration with foreign companies. Furthermore, the
global evolution of the genomics business in areas such as “Next Generation Sequencing” and “Consumer
Genomics” etc., in the coming future holds good business potential for bio-informatics companies in India.
Overall, with a large base of skilled and cost competitive scientific manpower, easy availability of raw material
such as plants and animals, and human genetic diversity, and a well-developing scientific infrastructure with a
big network of research laboratories, India has potential to gradually become a leading global player in
biotechnology. The setting up of a biotech regulator and more positive evolution of the intellectual property
regime in the country can further help in increasing India’s share in the global biotech industry.
The Indian biotech companies do look out to have access to the latest technology from the developed countries
as well as to the marketing support in the foreign markets. Indian researchers need to partner with quality
researchers from developed countries as such shared experiences often lead to adoption of best practices. A
number of bilateral programmes are already under implementation to promote such collaborations between
Indian and foreign companies/institutions.
It goes without saying that there is good scope for Swiss companies to explore collaboration with Indian
companies or set up their own R&D centres in India, that complement their business models and provide cost-
competitive quality infrastructure needed to achieve/enhance competitiveness in the fast moving globalisation
of businesses. Some Swiss biotech companies, e.g. Evolva, RCC Pharma, Roche, and Syngenta are already
functional in India, whereas Indian companies, such as Dr. Reddy’s Laboratories, Biocon, and Divis
Laboratories have their presence in Switzerland.
6. Important Contacts
Department of Biotechnology (DBT): http://dbtindia.nic.in/index.asp

Department of Science and Technology (DST): http://dst.gov.in
Association of Biotechnology Led Enterprises (ABLE): http://www.ableindia.org
India Brand Equity Foundation (IBEF): http://www.ibef.org
Bio Spectrum Magazine: http://biospectrumindia.ciol.com
th
Date: 14 October, 2009
Author: Mohinder Nayyar

Author’s Address: Swiss Business Hub India
Embassy of Switzerland
Nyaya Marg, Chankayapuri,
New Delhi 110 021
Tel: 0091 11 26878372
E-mail: Mohinder.Nayyar@eda.admin.ch
Encl: A select list of India’s 100 Biotech Companies
A Select List of India’s 100 Biotech Companies
ABL Biotechnologies Ltd
No.55, Third East Street,
Kamaraj Nagar, Tiruvanmiyur,
Chennai
600 041
Tel: 044 42020501/ 42020502.
Fax: 044 42020957
E-mail : mdo@ablbiotechnologies.com
http://www.ablbiotechnologies.com
Accutest Research Lab (I) Pvt. Ltd.

A-31, TTC Industrial Area
Khairane MIDC, Thane Belapur Road
Navi Mumbai
400 709
Tel: 022 2778 0718 / 19 / 20
Fax: 022 2778 0721
E-mail: business@accutestindia.com
www.accutestindia.com
Acton Biotech (India) Pvt. Ltd

th
4 Floor, Banoo Coyaji Building
KEM Hospital
Rastapeth
Pune
411 011
Tel: 020 3231 9395-2605 1094
Email: info@actonbiotech.com
www.actonbiotech.com
Advanced Enzyme Technologies Ltd

'A' Wing, Sun Magnetica,
5th Floor, Accolade Galaxy,
LIC Service Road, Louisewadi,
Thane
400 604.
Tel: 022-2583 8350 –54
Fax: 022-25835159.
Email: info@enzymeindia.com
http://www.enzymeindia.com
Advinus Therapeutics Pvt. Ltd.

Quantum Towers
Plot No 9, Rajiv Gandhi Infotech Park, Phase – I
Hinjewadi
Pune
411 057
Tel: 020 6653 9600
Fax: 020 6653 9620
E-mail: info@advinus.com
www.advinus.com
AG Bioteck Laboratories (India) Limited
Bachupalli (Vill.),
Qutabbullapur (M),
Kukatpalli, R.R. Dist.,
Hyderabad
500 072.
Tel/Fax: 040 - 23045884,
E-mail: agbiotek@yahoo.com
www.agbiotek.com
Ajanta Pharma Limited

98, Ajanta House
Charkop
Kandivili West
Mumbai
400 067
Tel: 022 6606 1000
Fax: 022 6606 1200 / 1300
Email: info@ajantapharma.com
www.ajantapharma.com
Ajeet Seeds Limited

Gut No.233, Chitegaon.
Tq. Paithan Dist.
Aurangabad.
431105
Tel : 02431- 251444, 251445, 251805.
Fax: 02431- 251833.
Email : aurangabad@ajeetseed.co.in
http://www.ajeetseed.co.in
Anil Products Limited (Anil Biochem)

Anil Road
P.O. Box 10009
Ahmedabad
380025
Tel: 079-2220 3222
Fax: 079-2220 0731
Emal: info@anil.co.in
http://www.anil.co.in
Animal Biotech (Bangalore) Pvt. Ltd.

33, 2nd Cross, Krishna Reddy Layout,
Bommanhalli
Bangalore
560068
Tel : 080-25731528
Fax: 080-25919566
E-mail: anibio@hotmail.com
Aptuit Laurus Private Limited
2nd Floor, Serene Chambers
Road # 7, Banjara Hills
Hyderabad
500 034
Tel: 040 3980 4333-2342 0500
Fax: 040 23420 503
Email: info@aptuitlaurus.com
www.aptuitlaurus.com
Asiatic Clinical Research Pvt. Ltd.

169/53, 14th Main Road
1st Block East
Jayanagar
Bangalore
560 011
Tel : 080 4168 1122 / 33 / 44
Fax : 080 4121 3841
Email: info@asiaticlinical.com
www.asiaticlinical.com
Aurigene Discovery Technologies Limited

39-40, KIADB Industrial Area
Electronic City Phase II, Hosur Road
Bangalore
560 100
Tel: 080 2852 1314 - 1316 - 8943
Fax: 080 2852 6285
E-mail: partnering@aurigene.com
www.aurigene.com
Avesthagen Limited
Discoverer, 9th Floor
International Technology Park
Whitefield Road
Bangalore
560 066
Tel: 080-2841 1665/2308/2770/2766
Fax: 080-2841 8780
E-mail: info@avesthagen.com
www.avesthagen.com
AVT Biotechnology
Plot No. 66, Kinfra Export Promotion Industrial Parks Ltd
Kusumagiri P.O
Cochin
682 030
Tel: 0484-2415177-2415178-2413177
Fax: 0484-2415179
E-mail : lji@airtelmail.in
http://www.avtbiotech.com/
Bangalore Biotech Labs Pvt. Ltd.
# 49/2, Gubbi Cross, Off Hennur Cross
Hennur - Bagalur Road, Kothanur
Bangalore
560 077
Tel: 080 6530 9009-9006
Fax: 080 2846 5668
E-mail: biotrain@biozeen.com
www.biozeen.com
Bangalore Genei
6, VI Main, BDA Industrial Suburb
Near SRS Road, Peenya
Bangalore
560 058
Tel: 080 2839 1453 / 6894 / 2837 8057
Fax: 080 2839 2825
E-mail: genei@sanmargroup.com
www.bangaloregenei.com
Bharat Biotech International Ltd.

Genome Valley, Shameerpet
Hyderabad
500 078
Tel: 040 2348 0567-2875 7836
Fax: 040 2348 0560
Email: info@bharatbiotech.com
www.bharatbiotech.com
Bharat Serums and Vaccines Ltd.

Hoechst House, 16th Floor
Nariman Point
Mumbai
400 021
Tel: 022 6656 0900
Fax: 022 6656 0901
E-mail : corporate@bharatserums.com
www.bharatserums.com
Bhat Bio-tech India (P) Ltd.

11-A, 4th Cross
Veerasandra Industrial Area
Electronics City
Bangalore
560 100
Tel: 080 4351 4000
Fax: 080 4351 4001
E-mail: bhatbiotech@vsnl.net
www.bhatbiotech.com
Bi Biotech
328, Ansal Chamber II
6 Bhikaji Cama Place
New Delhi
110 066
Tel: 011 2610 1271
Fax: 011 2610 1273
E-mail : Info@BiotechIndia.com
www.biotechindia.com
Bigtec Private Limited

#100/1, 3rd Floor, Anchorage-1,
Richmond Road,
Bangalore
560 025
Tel: 080 4001 9999
Email: info@bigtec.co.in
http://www.bigtec.co.in
BioCin Bioproducts Pvt. Ltd.

401 Shanti Soudha Erramanzil
Hyderabad
500 082
Tel: 040 23316288
E-mail: info@biocin.com
http://www.biocin.com
Biocon India
20th KM, Hosur Road
Electronics City
Bangalore
560 100
Tel: 080 2808 2808
Fax: 080 2852 3423
Email: contact.us@biocon.com
www.biocon.com
Bioserve Clinical Research Pvt Ltd

6-56/6/1A, Opp: IDPL
NH9, Balanagar
Hyderabad
500 037
Tel: 040 2377 0873 - 74
Fax: 040 2377 0877
E-mail: bd@bioserve.co.in
www.bioserve.co.in
Biovel Life Sciences (P) Limited
Sy.No.16, Ekarajapura
Hasigala (Post), Sidlagatta Road
Hosakote
Bangalore
562 114
Tel: 080-27971111
Fax: 080-27971121
E-mail : info@biovel.net
www.biovel.net
Caliber Technologies Pvt. Ltd.

401, 406, Bhanu Enclave, Model Colony
Hyderabad
500038
Tel: 040-23811322
Fax: 040-23817922
Email: sekhar@caliberindia.com
http://www.caliberindia.com
Camson Bio Technologies Ltd.

No.223, 1st Main
Domlur 2nd Stage
Bangalore
560 071
Tel: 080 2535 5138
Fax: 080 2535 2232
E-mail: info@camsonbiotechnologies.com
www.camsonbiotechnologies.com
Celestial Labs Limited

Plot No: 231/A, Road No.12,
MLA Colony, Banjara Hills,
Hyderabad
500034
Tel: 040 2354 0008
Fax: 040 2354 2844
E-mail: reach@celestiallabs.com
http://www.celestiallabs.com
Chembiotek
Block BN, Sector V
Salt Lake City
Kolkata
700 091
Tel: 033 2367 3151 - 52 - 53
Fax: 033 2367 3058
www.chembiotek.com
Concord Biotech Limited
302, Sakar III,
Opp. Old Gujarat High Court,
Off. ITO Circle,
Ahmedabad
380 014.
Tel: 079 27544998 / 27543557
Fax: 079 27540802
E-mail: sales@concordbiotech.com
http://www.concordbiotech.com
Connexios Life Science Pvt. Ltd.

#49, Shilpa Vidya
First Main Road, JP Nagar 3rd Phase
Bangalore
560 078
Tel : 080 4121 0672 - 587 - 5491 -92
Fax : 080 4121 0705
E-mail: info@connexios.com
http://www.connexios.com/
Dr. Reddy’s Laboratories Ltd.

Greenlands
Ameerpet
Hyderabad
500 016
Tel: 040 2373 1946 /7/8/9/50
Fax: 040 2373 1955
Email: businessdevelopment@drreddys.com
www.drreddys.com
DSS Imagetech Pvt. Ltd.

A-5 Mohan Co-op Indl. Estate
Mathura Road
New Delhi
110044
Tel: 011-30886715 / 17 / 35 / 66
Fax: 011-26959382
http://www.dssimage.com
Fermenta Biotech Limited

DIL Complex,
Ghodbunder Road,
Thane (West)
400 610
Tel. : 022 6798 0888
Fax : 022 6798 0999
Email : fermenta@fermentabiotech.com
http://www.fermentabiotech.com
Fortune Biotech Ltd.
6-6-125, Kavadiguda
Secunderabad
500380
Tel: 040-27531726
Fax: 040-27536089
E-mail: info@fortunebiotech.com
http://www.fortunebiotech.com
Frontier Tissueline
(Bio-science unit of Frontier Lifeline)
R-30-C Ambattur Industrial
Estate Road,
Mogappair,
Chennai
600 101
Tel: 044 42017575, 26564224
E-mail: drkmc@frontierlifeline.com
http://www.frontierlifeline.com/
GangaGen Biotechnologies Pvt Ltd.

No 12, 5th Cross, Raghavendra Layout
Opposite MEI Ltd,
Tumkur Road
Yeshwanthpur
Bangalore
560 022
Tel: 080 4062 1300 to 4062 1328
Fax: 080 4062 1329
E-mail: info@gangagen.com
www.gangagen.com
Genetix Biotech Asia Pvt. Ltd

71/1, Shivaji Marg,
New Delhi
110 015.
Tel: 011-4502-70000
Fax: 011-2541-9631
E-mail: nfo@genetixbiotech.com
http://www.genetixbiotech.com
Genotex International
# 4B, S.P.Biotech Park
Turkapalli Village,
Shameerpet Mandal, R.R.District
Andhra Pradesh
Tel: 040.22373438, Mo.: 98492 03303
E-mail: devenderreddy@genotex.net
http://www.genotex.net
Genotypic Technology
#259, „Apurva“, 4th Cross
80 Feet Road, R.M.V. 2nd Stage
Bangalore
560 094
Tel : 080 4053 8300-3293 4943-2351 6444
Fax : 080 2351 6555-4053 8222
Email: genomics@genotypic.co.in
www.genotypictech.com
Geomarine Biotechnologies
No.5/3,Fourth Street,
Chowdry Nagar, Valasaravakkam,
Chennai
600087
Tel: 044-32927036
Telefax: 044-24861568
E-mail: enquires@geomarinebiotech.com
http://www.geomarinebiotech.com
Green Signal Bio Pharma Pvt. Ltd.

Aarti Arcade , III floor
Chennai
600 004
Tel: 044 2811 2244
Fax: 044 2811 2233
E-mail: gsbpl@gsbpl.com
www.gsbpl.com
Greenearth Biotechnologies Ltd.

14A, Jigani Industrial Area
Bangalore
562 106
Tel: 080 9378 2556
Fax: 080 9378 2556
Email: sjn@greenearthbiotech.com
www.greenearthbiotech.com
Growmore Bio-tech Ltd.

#41-B, SIPCOT Phase-II
Hosur
635 109
Tel: 04344 260564, 260565
Fax: 04344 260560
E-mail: growmore@vsnl.com
www.growmorebiotech.com
Haffkine Bio-Pharma Corpn. Ltd.

Acharya Donde Marg, Parel
Mumbai
Tel: 022 2412 9320-21
Fax : 022 2416 8578
E-mail: mkt@vaccinehaffkine.com
www.vaccinehaffkine.com
High-tech Agri Services
# 490, 5th Cross, 5th Main,
2nd block, R.T.Nagar,
Bangalore
560032
Tel: 080 - 23634371
Fax : 080-41697171
E-Mail: info@hightechagri.com
http://www.hightechagri.com
Hindustan Bio Sciences Limited

Plot No. 31, Street No. 2, Sagar Society,
Road No. 2, Banjara Hills,
Hyderabad.
Tel: 040 23555161, 5171.
Fax: 040 2354 9411
Email: pharma@hindustanbio.com
www.hindustanbio.com
H.U. Gugle Biotech Pvt. Ltd

No. 23, P.O. Box No. 14,
Binnamangala Village,
Devanahalli Taluk,
Bangalore Dist.
562 110
Tel: 080 768 0669 / / 080 5760 9502
E-mail: info@hugugle.com
http://www.hugugle.com
Imperial Life Sciences (P) Limited

463 Pace City II, Sector - 37,
Gurgaon
122 001
Tel: 0124 - 4559800 - 99
Fax 0124 - 4559801
E - mail : info.bioservices@imperialls.com
http://www.imperialls.com
Indian Immunologicals Ltd.

Road # 44, Jubilee Hills
Hyderabad
500 033
Tel: 040 2354 4585 - 4593
Fax: 040 23544007
www.indimmune.com
Indigene Pharmaceuticals, Pvt. Ltd.

Indigene House
Road No. 14, Banjara Hills
Hyderabad
500 034
Tel: 040 2348 7000
Fax: 040 2354 8478
http://www.indigenepharma.com
Indovax
Corporate Heights,
SCO - 24, Sector - 14,
Gurgaon
122001
Tel.: 0124-2315044 / 45 / 46
Fax : 0124-2314680
E-mail: mail@indovax.com
http://www.indovax.com
Indus Biotech Private Limited India

1 Rahul Residency,
Off Salunke Vihar Road,
Kondhwa
Pune
411048
Tel: 020 6478 5063/63
Fax: 020 2685 0039
E-mail: info@indusbiotech.com
http://www.indusbiotech.com
Intas Biopharmaceuticals Ltd.

Plot No. 423 / P / A/ GIDC
Sarkhej - Bavla Highway,
Moraiya, Taluka - Sanand,
Ahmedabad,
382 210
Tel: 02717 - 660100/01
Fax : 02717 – 251189
E-mail: business@intasbiopharma.co.in
http://www.intasbiopharma.co.in
International Panaacea Limited

E-34, Connaught Circus,
New Delhi
110 001
Tel: 011-23418880-86
Fax: 11-23418889
E-mail: info@iplbiotech.com
www.iplbiotech.com
J.K. Agri Genetics Limited

1-10-177, 4th floor, Varun Towers
Begumpet,
Hyderabad
500 016
Tel: 040 66316858
Fax: 040 27764943
E-mail: info@jkseeds.net
http://jkseeds.net
Jubilant Organosys
1A, Sector 16A
NOIDA
201 301
Tel: 0120-2516601-11
Fax: 0120-2516628-30
http://www.jubl.com/
Kaypeeyes Biotech Pvt. Ltd.

306-C, Hebbal Industrial Area
Metagalli Post
Mysore
570 016
Tel: 0821 528 0039
Fax: 0821 240 3694
Email: sales@kpsbio.com
www.kpsbio.com
Lifecare Innovations Pvt. Ltd.

B-589, Sushant Lok Phase - I,
Gurgaon
122 002,
Tel: 0124-4041932,
Fax: 0124-4041933,
Email: info@lifecareinnovations.com
http://www.lifecareinnovations.com/home.htm
Lumis Biotech Ltd.

501, Arun Chambers,
Tardeo,
Mumbai
400034
Tel: 022 66662690 / 91 / 92 / 93 / 94
Fax: 022 23515034
E-mail: lumis@kgenix.com
http://www.lumisbiotech.com
Maharashtra Hybrid Seed Company,

Dawalwadi,
PO Box 76,
Jalna,
431203
Tel: 02482-233881, 233882
Fax: 02482-262002
E-mail: info@mahyco.com
http://www.mahyco.com
Maps (India) Limited
302, Shapath-3,
Near GNFC Info Tower,
S.G. Road,
Ahmedabad
380054.
India.
Tel: 079 26859971-74
Fax: 079) 26859975
E-mail: info@mapsenzymes.com
http://www.mapsenzymes.com
Max Neeman International

Max House, GF-1
Dr. Jha Marg
Okhla
New Delhi
110 020
Tel: 011 2632 2816 - 2632 2824
Fax: 011 26322846
http://www.neeman-medical.com/
Metahelix Life Sciences Pvt Ltd

Plot No. 3, KIADB, 4th Phase
Bommasandra
Bangalore
560 099
Tel: 08110 - 414555
Fax: 08110- 415074
E-mail: info@meta-helix.com
www.meta-helix.com
MGL
758, 1st Floor
Udyog Vihar, Phase – 5
Gurgaon
122016
Tel: 0124 – 4505360
Fax: 0124 – 4505299
http://www.mgl.com
Microbax (India) Limited

3-6-108/1, Liberty Road
Himayat Nagar
Hyderabad
500 029
Tel: 040 55360055
Fax: 040 55360057
E-mail: info@microbax.com
www.microbax.com
Molecular Connections Private Limited
Kandala Mansions, # 2/2, Kariappa Road,
Basavanagudi,
Bangalore
560 004
Tel: 080 4120 5016
Fax: 080 4120 8956
E-mail: info@molecularconnections.com
http://www.molecularconnections.com
Multiplex Bio-Tech Pvt. Ltd.

No. 180, 1st Main Road,
Mahalakshmi Layout,
Bangalore
560 086
Tel : 080-2349 7464/2349 4406
Fax : 080-2349 0647
E-mail: multiplex@multiplexgroup.com
http://www.multiplexgroup.com
Namdhari Seeds Pvt. Limited

Bidadi
Bangalore,
562109
Tel: 9845471271/ 9845471272/ 9845381817
Fax: 080-28602168
E-Mail: info@namdhariseeds.com
http://www.namdhariseeds.com
Nuziveedu Seeds Limited

NSL ICON,4 th Floor
Road No: 12
Banjara Hills
Hyderabad
500 034
Tel: 040-3051 4444
Fax: 040 2332 7919
E-mail: info@nuziveeduseeds.co.in
www.nuziveeduseeds.com
Ocimum Biosolutions
6th Floor, Reliance Classic
Road No. 1
Banjara Hills
Hyderabad
500 034
Tel: 040 6698 6700
Fax: 040 6662 7205
E-mail:hyd@ocimumbio.com
www.ocimumbio.com
Organica Biotech Pvt. Ltd.
36, Ujagar Industrial Estate
W.T. Patil Marg
Govandi
Mumbai
400 088
Tel: 022 6797 5150
Fax: 022 6797 5149
E-mail: postmaster@organicabiotech.com
http://www.organicabiotech.com/
Panacea Biotec Ltd.

B-1 Extn./ A-27
Mohan Co-op. Industrial Estate
Mathura Road
New Delhi
110 044
Tel: 011-41578021
Fax: 011-41679060
E-mail: corporate@panaceabiotec.com
www.panaceabiotec.com
Piramal Healthcare Ltd.

1st floor, D - Mart Building
Goregaon Mulund Link Rd
Mulund West
Mumbai
400 080
Tel: 022 3953 6666
E-mail: corporate.communication@piramal.com
piramalhealthcare.com
Polyclone Bio Services Pvt. Ltd.

# 47, 4th Main, 25 th Cross
Karesandra, Banashankari, 2nd Stage
Bangalore
560 070
Tel: 080 2671 7181
Fax: 080 2671 4849
E-mail: info@polyclonebio.com
www.polyclonebio.com
PREMAS Biotech Pvt. Ltd.,

Plot No. 77, Sector 4,
IMT Manesar,
Gurgaon
122050,
Tel: 0124-4546600
Fax: 0124-4365221
Email: contact@premasbiotech.com
http://www.premasbiotech.com
Proalgen Biotech Limited
#15, III Avenue, Indra Nagar
Adyar,
Chennai
600 020
Tel: 044 - 2445 4332
Fax: 044 - 2445 4756
E-mail: info@proalgenbiotech.com
http://www.proalgenbiotech.com
Rasi Seeds (P) Ltd

273, Kamarajanar Road
P.O. Box No: 30
Attur
636 102
Tel: 04282-241007, 242007
Fax: 04282-242558
E-mail: rasimail@rasiseeds.com
http://www.rasiseeds.com/
Reliance Life Sciences,

Biotechnology Division
R-282, TTC Industrial Area of MIDC,
Thane-Belapur Road, Rabale,
Navi Mumbai
400 701
Tel: 022 4067 8000
Fax: 022 4067 8099
E-mail: info@relbio.com
http://www.rellife.com
RFCL Limited
A-3, Okhla Industrial Area, Phase-I
New Delhi
110 020
Tel: 011 42395700 (Direct), 41609171-75 (Board)
Fax : 011 41609189
E-mail : info@rfcl.in
http://www.rfcl.in
Richcore Lifesciences Pvt. Ltd

#168, Sri Sapthagiri
Ist Floor, II nd Main Road, East of N.G.E.F
Kasturinagar
Bangalore
560 043
Tel: 080 4044 7474
Fax: 080 4044 7484
Email :info@richcoreindia.com
www.richcoreindia.com
Rossari Biotech
401, Omega, Main Street,
Hiranandani Gardens,
Powai,
Mumbai
400 076
Tel :: 022-25709200 / 01
E-mail: info@rossarimail.com
www.rossari.com
Serum Institute of India Ltd.

212/2 Hadapsar
off Soli Poonawalla Road
Pune
411 028
Tel: 020 2699 3900
Fax: 020 2699 3921
E-mail: contact@seruminstitute.com
www.seruminstitute.com
Spinco Biotech
4, Vaidyaram Street, T.Nagar,
Chennai
600 017
Tel: 044 2434 0174
Fax: 044 2434 0761
E-mail: info@spincotech.com
http://www.spincotech.com
Sri Biotech Laboratories India Limited

#211, Bhavya’s Sree Arcade,
Bata Complex, Erragadda,
Hyderabad
500 018.
Tel : 040-23702823, 23701153
E-mail-: infosribio@gmail.com
http://www.sribio.com
Strand Life Sciences

237 Sir C.V. Raman Avenue
Rajmahal Vilas, Sadashivnagar
Bangalore
560 080
Tel: 080 4078 7263
Fax: 080 2361 8996
http://www.strandgenomics.com/
Sun Agro Biosystem Private Ltd
3/340, Main Road,
Madanandapuram, Porur,
Chennai
600 116
Tel: 044 – 2482 7652 / 6984
Fax: 044 – 2482 7998
Email: sunagro@vsnl.net
http://www.sunagrobiosystem.com
Sungro Seeds Limited

3d floor,Sungro Camber,
B.N. Block,
Local Shopping Center,
Shalimar Bagh,
Delhi
110088
Tel : 011-27471117, 27488272
Fax : 011-27470333
Email : ceo@sungroseeds.com
http://www.sungroseeds.com
Synergy Biotechnologies
#1-58, Snehapuri, Nacharam,
Hyderabad
500 076
Tel: 040-27174095
Fax: 040-27176365
E-mail: info@synergybiotech.net
http://www.synergybiotech.net
Syngene International Ltd.

Biocon Park , Plot 2&3,
Bommasandra Industrial Estate - Phase-IV
Bommasandra-Jigani Link Road,
Bangalore
560 099
Tel: 080 2808 2808
Fax: 080 2808 3150
E-mail: Narendra.kumar@syngeneintl.com
http://www.syngeneintl.com
Tex Biosciences Pvt. Ltd.

"Textan House" 75, Fourth Avenue,
Ashok Nagar
Chennai
600 083
Tel : 044-42988700
Fax : 044-42988787
E-mail : info@texbiosciences.com
www.texbiosciences.com
Themis Medicare Ltd.
11/12, Udyog Nagar
S.V.Road, Goregaon West
Mumbai
400 104
Tel: 022 6760 7080
Fax: 022 2874 6621
www.themismedicare.com
Torrent Gujarat Biotech Limited

Torrent House,
Off Ashram Road,
Ahmedabad
380 009
Tel: 079 2658 5090,2658 3060
Fax: 079 2658 2100
Email: ho@biotech-torrent.com
http://www.torrentlimited.com/tgbl.htm
Unique Biotech Limited

Plot No. 123, Phase-V, I.D.A.
Jeedimetla
Hyderabad
500 055
Tel: 040 2319 3092
Fax: 040 2309 3089
E-mail: info@uniquebiotech.com
www.uniquebiotech.com
VARDA Biotech (P) Ltd.

#110 & 111, Kartik complex
New Link Road
Andheri West
Mumbai
400 053
Tel: 022 6693 5686-2673 0141-2673 4258
Fax: 022 6693 5687
www.vardabiotech.com
Venkateshwara Hatcheries
Venkateshwara House, S.No. 114/A/2,
Pune-Sinhagad Road, Viththalwadi,
Pune
411 030
Tel: 020-24251530 to 41
Fax: 020-24251077
E-mail: response@venkys.com
http://www.venkys.com
VINS Bioproducts Ltd.
806, Essjay House,
Road No.: 3,
Banjara Hills,
Hyderabad
500 034
Tel: 040-23354550, 23353540, 55622962
Fax: 040-23350410
E-mail: info@vinsbio.in
www.vinsbio.in
VLife Sciences Technologies

Pride Purple Coronet
287 Vibhag 39/563, Baner Road,
Pune
411 045
Tel: 020 2729 1590
Fax: 020 2729 1591
E-mail: info@vlifesciences.com
http://www.vlifesciences.com
Yash Medicare Private Limited,

Nr. Sabar Dairy, Talod Road,
PO. Hajipur,
Himatnagar, Gujarat
383 006
Tel: 02772-226 099
Fax: 02772-229 399
Email: info@ympl.net
http://www.ympl.net

Biotechnology 2009 India

Încărcat de

Informații document

Descriere originală:

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Biotechnology 2009 India

Încărcat de

Drepturi de autor:

Formate disponibile

India

Swiss Business Hub India

Download from: www.osec.ch

2. Indian Biotechnology Industry

Bio-pharma 671 871 1148 1457 1683

Biotech Industry- Exports Vs Domestic Sales 2007-08

Bio-pharma 976 707

0 200 400 600 800 1000 1200 1400 1600 1800

Source: India Brand Equity Foundation – IBEF / ABLE-Biospectrum Survey

Share of different segments in biotech exports during 2007-08

Bio-pharma Bio-services Bio-agri Bio-industrial Bio-informatics

Source: Indian Brand Equity Foundation – IBEF / Biospectrum

Top 20 Biotech Companies (Revenue-wise)

Rank Company 2007-08 2006-07 Y-o-Y

3. Potential Growth of the Biotechnology Industry

Nevertheless, the following factors will be driving the growth:

Department of Biotechnology (DBT): http://dbtindia.nic.in/index.asp

Author: Mohinder Nayyar

Encl: A select list of India’s 100 Biotech Companies

Accutest Research Lab (I) Pvt. Ltd.

Acton Biotech (India) Pvt. Ltd

Advanced Enzyme Technologies Ltd

Advinus Therapeutics Pvt. Ltd.

Ajanta Pharma Limited

Ajeet Seeds Limited

Anil Products Limited (Anil Biochem)

Animal Biotech (Bangalore) Pvt. Ltd.

Asiatic Clinical Research Pvt. Ltd.

Aurigene Discovery Technologies Limited

Bharat Biotech International Ltd.

Bharat Serums and Vaccines Ltd.

Bhat Bio-tech India (P) Ltd.

Bigtec Private Limited

BioCin Bioproducts Pvt. Ltd.

Bioserve Clinical Research Pvt Ltd

Caliber Technologies Pvt. Ltd.

Camson Bio Technologies Ltd.

Celestial Labs Limited

Connexios Life Science Pvt. Ltd.

Dr. Reddy’s Laboratories Ltd.

DSS Imagetech Pvt. Ltd.

Fermenta Biotech Limited

GangaGen Biotechnologies Pvt Ltd.

Genetix Biotech Asia Pvt. Ltd

Green Signal Bio Pharma Pvt. Ltd.

Greenearth Biotechnologies Ltd.

Growmore Bio-tech Ltd.

Haffkine Bio-Pharma Corpn. Ltd.

Hindustan Bio Sciences Limited

H.U. Gugle Biotech Pvt. Ltd

Imperial Life Sciences (P) Limited

Indian Immunologicals Ltd.

Indigene Pharmaceuticals, Pvt. Ltd.

Indus Biotech Private Limited India

Intas Biopharmaceuticals Ltd.

International Panaacea Limited

J.K. Agri Genetics Limited

Kaypeeyes Biotech Pvt. Ltd.

Lifecare Innovations Pvt. Ltd.

Lumis Biotech Ltd.

Maharashtra Hybrid Seed Company,

Max Neeman International

Metahelix Life Sciences Pvt Ltd